Ac-SDKP, a marker of the angiotensin-converting enzyme activity?;L'Ac-SDKP: Une clé pour comprendre certains effets des inhibiteurs de l'enzyme de conversion?

Annales de Biologie Clinique

Volumn 64, Issue 1, 2006, Pages 11-16

  Mimouni, S ^a   Raffaitin, C ^a   Corcuff, J B ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Ac SDKP; Angiotensin converting enzyme; Diabetes; Hypertension

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GROWTH INHIBITOR; OLIGOPEPTIDE; SERASPENIDE; TRANSFORMING GROWTH FACTOR BETA;

CARDIOVASCULAR DISEASE; CELL DIVISION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; HEART; HEART INFARCTION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; STEM CELL;

CARDIOVASCULAR DISEASES; CELL DIVISION; GROWTH INHIBITORS; HEART; HUMANS; MYOCARDIAL INFARCTION; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 32044450751     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation : purification and determination of its structure. Proc Natl Acad Sci USA 1989 ; 86 : 779-82.
2. Carde P. Inhibiteurs de l'hématopoièse : de la physiologie à la therapeutique. Bull Acad Natl Med 1994 ; 178 : 793-803 ; discussion 804-6.
3. Robinson S, Lenfant M, Wdzieczak-Bakala J, Melville J, Riches A. The mechanism of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell proliferation. Cell Prolif 1992 ; 25: 623-32.
4. Grillon C, Bonnet D, Mary JY, Lenfant M, Najman A, Guigon M. The tetrapeptide AcSerAspLysPro (Seraspenide), a hematopoietic inhibitor, may reduce the in vitro toxicity of 3′-azido-3′-deoxythymidine to human hematopoietic progenitors. Stem Cells 1993 ; 11 : 455-64.
5. Gaudron S, Grillon C, Thierry J, Riches A, Wierenga PK, Wdzieczak-Bakala J. In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation. Stem Cells 1999 ; 17 : 100-6.
6. Cappelaere P, Hecquet B, Rolland F, et al. Essai randomisé avec placebo de myéloprotection par le goralatide des patients presentant un carcinome épidermoide des voies aérodigestives supérieures ou de l'œsophage, traités par l'association carboplatine-5 fluorouracile. Bull Cancer 1995 ; 82 : 732-7.
7. Lombard MN, Sotty D, Wdzieczak-Bakala J, Lenfant M. In vivo effect of the tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro, on the G1-S transition of rat hepatocytes. Cell Tissue Kinet 1990 ; 23 : 99-103.
8. Michel JB. Renin-angiotensin system and vascular remodelling. Med Sci (Paris) 2004 ; 20 : 409-13.
9. Peng H, Carretero OA, Brigstock DR, Oja-Tebbe N, Rhaleb NE. Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension 2003 ; 42 : 1164-70.
10. Pokharel S, Rasoul S, Roks AJ, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 2002 ; 40: 155-61.
11. Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 2001 ; 37 : 827-32.
12. Yang F, Yang XP, Liu YH, et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004 ; 43 : 229-36.
13. Pokharel S, van Geel PP, Sharma UC, et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 2004 ; 110 : 3129-35.
14. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998 ; 47 : 859-66.
15. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 ; 414 : 813-20.
16. Border WA. Transforming growth factor-beta and the pathogenesis of glomerular diseases. Curr Opin Nephrol Hypertens 1994 ; 3 : 54-8.
17. Shibuya K, Kanasaki K, Isono M, et al. N-acetyl-seryl-aspartyl-lysyl- proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005 ; 54 : 838-45.
18. Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection : the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999; 33 (Suppl. 1): S16-S20; discussion S41-3.
19. Iwamoto N, Xano HJ, Yoshioka T, et al. Acetyl-seryl-aspartyl-lysyl- proline is a novel natural cell cycle regulator of renal cells. Life Sci 2000 ; 66 : PL221-PL226.
20. Kanasaki K, Koya D, Sugimoto T, Isono M, Kashiwagi A, Haneda M. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol 2003 ; 14 : 863-72.
21. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline : a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30: 1015-9.
22. Chisi JE, Briscoe CV, Ezan E, Genet R, Riches AC, Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol 2000 ; 109 : 563-70.
23. Azizi M, Ezan E. Response to " Le Meur, Aldigier, Praloran : Is plasma Ac-SDKP level a reliable marker of chronic angiotensin-converting enzyme inhibition in hypertensive Patients ? ". Hypertension 1998 ; 31 : 1201-2.
24. Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure : relationship with erythropoietin requirements. Am J Kidney Dis 2001 ; 38 : 510-7.
25. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993 ; 268 : 9496-503.
26. Pradelles P, Frobert Y, Creminon C, Liozon E, Masse A, Frindel E. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun 1990 ; 170 : 986-93.
27. Junot C, Pruvost A, Creminon C, Grognet JM, Benech H, Ezan E. Characterization of immunoreactive acetyl-Ser-Asp-Lys-Pro in human plasma and urine by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 2001 ; 752 : 69-75.
28. Cheng J, Grande JP. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med (Maywood) 2002 ; 227 : 943-56.
29. Dunker N, Krieglstein K. Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis. Eur J Biochem 2000 ; 267 : 6982-8.